Achieving Good Perioperative Outcomes After Pancreaticoduodenectomy in a Low-volume Setting: a 25-year Experience
Overview
Authors
Affiliations
Perioperative mortality following pancreaticoduodenectomy has improved over time and is lower than 5% in selected high-volume centers. Based on several large literature series on pancreaticoduodenectomy from high-volume centers, some defend that high annual volumes are necessary for good outcomes after pancreaticoduodenectomy. We report here the outcomes of a low annual volume pancreaticoduodenectomy series after incorporating technical expertise from a high-volume center. We included all patients who underwent pancreaticoduodenectomy performed by a single surgeon (ADC.) as treatment for periampullary malignancies from 1981 to 2005. Outcomes of this series were compared to those of 3 high-volume literature series. Additionally, outcomes for first 10 cases in the present series were compared to those of all 37 remaining cases in this series. A total of 47 pancreaticoduodenectomies were performed over a 25-year period. Overall in-hospital mortality was 2 cases (4.3%), and morbidity occurred in 23 patients (48.9%). Both mortality and morbidity were similar to those of each of the three high-volume center comparison series. Comparison of the outcomes for the first 10 to the remaining 37 cases in this series revealed that the latter 37 cases had inferior mortality (20% versus 0%; P = 0.042), less tumor-positive margins (50 versus 13.5%; P = 0.024), less use of intraoperative blood transfusions (90% versus 32.4%; P = 0.003), and tendency to a shorter length of in-hospital stay (20 versus 15.8 days; P = 0.053). Accumulation of surgical experience and incorporation of expertise from high-volume centers may enable achieving satisfactory outcomes after pancreaticoduodenectomy in low-volume settings whenever referral to a high-volume center is limited.
Early Postoperative Vital Signs Predict Subsequent 90-Day Mortality After Pancreaticoduodenectomy.
Nerwal T, Qoshe L, Iyer S, Medina G, Felix A, Lavu H J Gastrointest Surg. 2023; 27(8):1660-1667.
PMID: 37106207 DOI: 10.1007/s11605-022-05410-0.
Key drug-targeting genes in pancreatic ductal adenocarcinoma.
Sakharkar M, Dhillon S, Mazumder M, Yang J Genes Cancer. 2021; 12:12-24.
PMID: 33884102 PMC: 8045979. DOI: 10.18632/genesandcancer.210.
Kim S, Yoon Y, Han H, Cho J, Choi Y, Lee B Surg Endosc. 2020; 35(6):2870-2878.
PMID: 32548654 DOI: 10.1007/s00464-020-07724-z.
Chang S Ann Surg Treat Res. 2019; 97(3):130-135.
PMID: 31508393 PMC: 6722292. DOI: 10.4174/astr.2019.97.3.130.
Song K, Kim S, Lee W, Hwang D, Lee J, Kwon J Surg Endosc. 2019; 34(3):1343-1352.
PMID: 31214805 DOI: 10.1007/s00464-019-06913-9.